Approval
FDA Approves Venglustat
Sanofi announced FDA approval of venglustat for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg, describing it as the first US treatment for those symptoms. In the 43-patient phase 3 LEAP2MONO trial, venglustat showed a significant neurological benefit over imiglucerase; platelet count did not meet the noninferiority criterion. Venglustat is under review in the EU, and Sanofi plans further submissions in other regions in 2026.
- Drugvenglustat
- CompanySanofi
- TargetUDP-glucose ceramide glucosyltransferase
- TargetProtein N-terminal methyltransferase 1
- TrialNCT05222906
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.